MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH44250D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company's lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It also developed a line of breath-powered, dry powder inhalers. Mannkind develops its products based on Technosphere drug delivery platform, its proprietary formulation technology. It also utilizes inhalation profiling technologies such as BluHale. It conducts its manufacturing operations in Danbury, Connecticut and sells its products in the US through a direct sales force. MannKind is headquartered in California, the US.

MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

MannKind and Biomm Enter into Distribution Agreement 12

MannKind Partners with JDRF 12

Licensing Agreements 13

Receptor Life Sciences Enters into Licensing Agreement with MannKind 13

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 14

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 15

Equity Offering 16

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 16

MannKind Raises USD36.2 Million in Private Placement of Shares 17

Mannkind Raises USD50 Million in Private Placment of Shares 18

MannKind Announces Public Offering Of Common Stock For USD50 Million 20

MannKind Completes Public Offering Of Common Stock And Warrants For USD92 Million 21

MannKind Completes Public Offering Of Units For USD86 Million 22

Debt Offering 23

MannKind Completes First Tranche Of Private Placement Of Notes For USD40 Million 23

MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For USD370 Million 25

MannKind Corp-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 29

Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 30

Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 32

Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 34

May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 35

Mar 14, 2016: MannKind Reports 2015 Fourth Quarter and Full Year Financial Results 36

Corporate Communications 37

Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 37

Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 38

Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 39

Feb 19, 2016: Alfred Mann Steps Down as Executive Chairman of Mannkind 40

Jan 11, 2016: MannKind Provides Update on Senior Management 41

Product News 42

Aug 01, 2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs 42

Jun 12, 2016: MannKind Announces Late-Breaking Data Demonstrating Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 43

Mar 08, 2017: MannKind and Charles Mattocks Announce "REVERSED"-America's First Docu-Series Tackling Diabetes 45

Feb 01, 2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 46

Other Significant Developments 47

Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MannKind Corp, Deals By Therapy Area, 2011 to YTD 2017 9

MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

MannKind and Biomm Enter into Distribution Agreement 12

MannKind Partners with JDRF 12

Receptor Life Sciences Enters into Licensing Agreement with MannKind 13

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 14

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 15

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 16

MannKind Raises USD36.2 Million in Private Placement of Shares 17

Mannkind Raises USD50 Million in Private Placment of Shares 18

MannKind Announces Public Offering Of Common Stock For USD50 Million 20

MannKind Completes Public Offering Of Common Stock And Warrants For USD92 Million 21

MannKind Completes Public Offering Of Units For USD86 Million 22

MannKind Completes First Tranche Of Private Placement Of Notes For USD40 Million 23

MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For USD370 Million 25

MannKind Corp, Key Competitors 26

MannKind Corp, Key Employees 27

MannKind Corp, Other Locations 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

MannKind Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16195
Site License
USD 500 INR 32390
Corporate User License
USD 750 INR 48585

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com